This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arribas, R. Articles by Peinado, M. A. Search for Related Content PubMed PubMed Citation Articles by Arribas, R. Articles by Peinado, M. A.

Prospective Assessment of Allelic Losses at 4p14–16 in Colorectal Cancer: Two Mutational Patterns and a Locus Associated with Poorer Survival¹

Institut de Recerca Oncològica [R. A., R-A. R., L. M., S. T., G. A., M. A. P.] and Institut Català d’Oncologia [G. C.], Hospital Duran i Reynals, L’Hospitalet, 08907 Barcelona; Departament de Biologia Cellular i Fisiologia, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, 08913 Barcelona [M. R., R. M.]; and Servei d’Oncologia and Laboratori d’Investigació Gastrointestinal, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona [E. M., G. C.], Spain

Previous studies have shown that allelic losses in a locus mapping to the chromosomal region 4p14–16 are indicative of poor prognosis in colorectal cancer. To further characterize the region involved and to confirm earlier observations, we have analyzed losses of heterozygosity (LOH) in nine microsatellite markers spanning this region in a prospective series of 181 colorectal carcinomas. The extent and the nature of the allelic imbalance were also ascertained by comparative genomic hybridization analysis of selected cases. The minimum common deleted region was confined to marker D4S2397 (LOH in 35% of the informative cases). Surrounding markers displayed LOH in 13–25% of informative cases and (other than the D4S2397 marker itself) showed a higher rate of allelic imbalances in association with mutations in the p53 tumor suppressor gene. Tumors with lymph node invasion also displayed increased rates of LOH in most markers. Regarding patient outcome, LOH solely at the D4S2397 locus was indicative of a shorter disease-free survival (P = 0.027). In consequence, two patterns of allelic loss are defined within the 4p14–16 region: (a) gross losses associated with tumor progression and probably attributable to the genomic instability related to the inactivation of the p53 tumor suppressor gene; and (b) specific losses limited to the D4S2397 locus (within an estimated fragment of 2 Mb) and associated with increased tumor aggressiveness. The presence of one or more putative tumor suppressor genes in this region is postulated.

This article has been cited by other articles:

				S. Leopoldo, B. Lorena, A. Cinzia, D. C. Gabriella, B. A. Luciana, C. Renato, M. Antonio, S. Carlo, P. Cristina, C. Stefano, et al. Two Subtypes of Mucinous Adenocarcinoma of The Colorectum: Clinicopathological and Genetic Features Ann. Surg. Oncol., May 1, 2008; 15(5): 1429 - 1439. [Abstract] [Full Text] [PDF]

				F Al-Mulla, S AlFadhli, A H Al-Hakim, J J Going, and M S Bitar Metastatic recurrence of early-stage colorectal cancer is linked to loss of heterozygosity on chromosomes 4 and 14q. J. Clin. Pathol., June 1, 2006; 59(6): 624 - 630. [Abstract] [Full Text] [PDF]

				G. Bardi, C. Fenger, B. Johansson, F. Mitelman, and S. Heim Tumor Karyotype Predicts Clinical Outcome in Colorectal Cancer Patients J. Clin. Oncol., July 1, 2004; 22(13): 2623 - 2634. [Abstract] [Full Text] [PDF]

				R.-A. Risques, V. Moreno, M. Ribas, E. Marcuello, G. Capella, and M. A. Peinado Genetic Pathways and Genome-Wide Determinants of Clinical Outcome in Colorectal Cancer Cancer Res., November 1, 2003; 63(21): 7206 - 7214. [Abstract] [Full Text] [PDF]

				F. Graziano and S. Cascinu Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann. Onc., July 1, 2003; 14(7): 1026 - 1038. [Abstract] [Full Text] [PDF]

				M. Koshiji, Y. Yonekura, T. Saito, N. Sakaida, Y. Uemura, and K. Yoshioka Genetic Alterations in Normal Epithelium of Colorectal Cancer Patients May Be a Useful Indicator for Subsequent Metachronous Tumor Development Ann. Surg. Oncol., July 1, 2002; 9(6): 580 - 586. [Abstract] [Full Text] [PDF]

				R S Houlston What we could do now: molecular pathology of colorectal cancer Mol. Pathol., August 1, 2001; 54(4): 206 - 214. [Abstract] [Full Text] [PDF]